What Juno is, and what it isn't

Juno is an educational and harm-reduction tool for people working with peptides. The single guiding principle: better information leads to better decisions. Everything here is built around that.

Not medical advice

Juno does not provide medical advice, diagnosis, or treatment. The peptide library, calculator, reconstitution guide, flashcards, and all AI-assisted features are informational. Any decision about starting, stopping, or modifying a peptide protocol should involve a qualified clinician who knows your full medical history.

Many peptides discussed are not FDA-approved

Peptides like BPC-157, TB-500, CJC-1295, and ipamorelin are sold as research compounds and are not approved by the FDA for human use. Some FDA-approved peptides — semaglutide, tirzepatide, tesamorelin — have specific approved indications and a body of human trial data. Most other claims you'll find online are not at that level of evidence. Juno's evidence-tier system exists to make this distinction visible, not to make decisions for you.

Evidence tiers reflect research quality, not endorsement

A peptide tagged Tier 1 has strong human RCT support for the specific indication shown. A Tier 3 peptide-indication pair has animal-only data — no claim about safety, efficacy, or wisdom of use is implied. Tiers are per peptide-indication pair, never per peptide. The same molecule can be Tier 1 for one indication and Tier 4 for another. Read every entry before drawing conclusions.

The calculator is math, not permission

The peptide calculator does the dilution and dose-volume math accurately. It will warn you about edge cases — sub-measurable volumes, over-capacity draws, suspect concentrations. It will not tell you whether a particular dose is appropriate for you. That's a clinical question.

What we will not do

• Recommend doses for anyone under 18.
• Recommend peptides during pregnancy or breastfeeding.
• Recommend protocols during active oncology treatment.
• Combine peptides with controlled substances or psychiatric medications without explicit clinician involvement.
• Soften an evidence tier because a peptide is popular.
• Sell, trade, or license your personal data.

Reach out if something looks wrong

We make mistakes. If you find an inaccurate citation, a stale dose range, or a tier that doesn't match the underlying literature, please tell us — editorial corrections come fast, and the corpus gets better when readers push back.

Last updated: 2026-04-30. By using Juno you confirm that you have read and understood this disclaimer.